STM JOURNALS

Research & Reviews: A Journal of
Medical Science and Technology
https://journals.stmjournals.com/rrjomst/

ISSN: 2319-3417 (Online)
ISSN: 2349-1272 (Print)
Volume 13, Issue 1, 2024
DOI (Journal): 10.37591/RRJoMST

Review RRJoMST

Revolutionizing Drug Delivery: Recent Advances in Pharmaceutical Dosage Forms

Srinatha N.[1,] *, Zaid Khan[2]

Abstract

Recent advances in pharmaceutical dosage forms revolutionize drug delivery, prioritizing targeted therapy and patient well-being. Enhanced drug carriers address complex medical challenges, from high-grade gliomas to ocular drug delivery, maximizing therapeutic efficacy while minimizing adverse effects. Traditional dosage forms like tablets and capsules undergo meticulous formulation and manufacturing processes, integrating Quality by Design principles for consistent product quality. Liquid formulations encounter stability challenges, necessitating rigorous stability testing and pH monitoring. Topical formulations, including creams, ointments, and patches, optimize drug absorption and retention, while advanced systems like nanotechnology-based delivery offer precise targeting and reduced toxicity. Biodegradable systems and personalized drug delivery represent groundbreaking advancements facilitated by the convergence of 3D printing and pharmacogenomics. This synergy allows for the customization of treatments to suit the unique biological profiles of individual patients, thereby significantly enhancing treatment outcomes and patient adherence. Regulatory oversight and comprehensive safety assessments play pivotal roles in ensuring the effectiveness and safety of these innovative drug delivery technologies, instilling confidence in both healthcare providers and patients alike. Moreover, the economic ramifications of such advancements are profound, with potential cost savings and improved resource allocation. Looking ahead, emerging trends like immune checkpoint therapy and lipid-based nano-drug delivery promise to further revolutionize personalized medicine, offering new avenues for precise and targeted therapeutic interventions. Together, these developments herald a promising era characterized by unparalleled precision, efficacy, and patient-centric care in the field of drug delivery.

Keywords: Pharmaceutical dosage forms, Drug delivery, Targeted therapy, Nanotechnology-based delivery, Personalized drug delivery, Immune checkpoint therapy.

INTRODUCTION

Drug delivery systems hold considerable importance in maximizing therapeutic effectiveness and enhancing patient well-being. They are engineered to administer medications to precise anatomical sites, facilitating focused therapy while mitigating the potential adverse effects linked with systemic drug dispersion. For instance, specialized drug delivery systems have been devised to address high-grade gliomas, the primary and most aggressive form of brain tumors. Such systems offer solutions to prevalent medical obstacles, including drug resistance, systemic adverse reactions, and restricted drug permeability owing to the blood-brain barrier [1]. Furthermore, drug delivery systems have the potential to enhance patient satisfaction through the provision of more convenient and minimally invasive routes of drug

***Author for Correspondence**
Srinatha N.
E-mail: srinathan304@gmail.com

[1,2]Researcher, Department of Pharmaceutics, Aditya Bangalore Institute of Pharmacy Education and Research, Yelahanka, Bengaluru, Karnataka, India

Received Date: March 06, 2024
Accepted Date: March 10, 2024
Published Date: April 15, 2024

Citation: Srinatha N., Zaid Khan. Revolutionizing Drug Delivery: Recent Advances in Pharmaceutical Dosage Forms. Research & Reviews: A Journal of Medical Science and Technology. 2024; 13(1): 77-89p.

application. For example, biomaterials have been harnessed for ocular drug delivery, encompassing the utilization of drug-eluting contact lenses. Such innovations aim to enhance patient adherence to treatment regimens and diminish the necessity for frequent dosing intervals [2]. Nonetheless, drug delivery systems are linked with distinct complexities spanning from postoperative issues, medication-induced adverse reactions, device malfunctions, to adverse events associated with refills [3]. As research progresses towards the development of innovative drug carriers and methodologies, there emerges an increasing potential for enhancing current therapeutic approaches and broadening the horizon of treatment options [4]. The progression of pharmaceutical dosage forms throughout history has witnessed notable advancements spurred by the necessity for enhanced drug delivery mechanisms, heightened patient adherence, and personalized therapeutic approaches. Essential landmarks and innovations encompass: In the 17th century, foundational terminology pertaining to dosage forms began to surface, encompassing Latin and Russian terminology evident in handwritten prescriptions and governmental pharmacopeia's [5]. And during the mid-20th century, the development of the multilayer tablet press facilitated the production of tablets with multiple layers containing various active pharmaceutical ingredients (APIs) [6]. In the early 21st century, the advent of Three-Dimensional Printing (3DP) has opened avenues for customized medication, enabling the creation of bespoke dosage forms tailored to the specific needs of individual patients [7].

Traditional Pharmaceutical Dosage Forms

Tablets: Formulation and Manufacturing

The formulation and manufacturing processes for tablets encompass various crucial steps and factors. Below is a summary derived from the referenced research findings.

Formulation Process

- ***Pre**-formulation Studies:* The pre-formulation investigations aim to elucidate the characteristics of excipients, including their flow behavior, compatibility, and tableting properties, thereby enhancing comprehension of their influence on pharmaceutical formulations [8].
- *Quality by Design (QbD):* A methodical strategy is employed for designing and refining formulations, with a central emphasis on identifying Critical Process Parameters (CPP) and Critical Quality Attributes (CQA), contributing to an enhanced understanding of the formulation process [9].
- *Excipients:* Typical excipients encompass super-disintegrants, hydroxypropyl methylcellulose (HPMC), xanthan gum, polyvinylpyrrolidone (PVPK30), mannitol, cross povidone, sodium starch glycolate, and colloidal silicon dioxide, commonly utilized in pharmaceutical formulations [10].
- *Design Space (DS):* Derived from study data, formulations are optimized by adjusting variables such as compression force and the concentration of super-disintegrants to enhance their effectiveness, as per academic inquiry [11]. Excipients:

Manufacturing Process

- *Quality by Design (QbD) Approach:* Utilized within manufacturing procedures to uphold and augment the caliber of produced goods.
- *Critical Quality Attributes (CQA):* Variables such as flow characteristics, granule attributes, uniformity of blends, tablet aesthetics, dissolution kinetics, and drug release profiles are observed and evaluated [12, 13].
- *Process Parameters:* Enhanced through the Quality by Design (QbD) methodology for the optimization of mixing, granulation, lubrication, and tablet compression procedures [14].

These investigations underscore the significance of employing systematic methodologies such as Quality by Design (QbD) in both the formulation design and manufacturing procedures to uphold consistent product quality and enhance tablet attributes.

Capsules: Gelatin vs. Vegetarian Capsules

Formulation

- *Gelatin Capsules:* Historically utilized in the formulation of capsules, sourced from animal origins such as bovine or porcine skin and skeletal tissues [15].
- *Vegetarian Capsules:* Fabricated from botanical constituents such as hydroxypropyl methylcellulose (HPMC) or pullulan, thereby catering to the dietary preferences of vegetarian individuals and adherents of specific religious doctrines [16].

Advantages

Gelatin Capsules

1. Commonly embraced within the pharmaceutical sector due to their simplicity in manufacturing and their ability to seamlessly integrate with a diverse array of formulations.
2. Economically advantageous and demonstrate favorable stability across diverse storage environments [17].

Vegetarian Capsules

1. Rising in prominence in tandem with the growing consumer interest in plant-based and vegetarian-friendly goods [18].
2. Expanding market sector propelled by consumer inclinations toward alternatives not derived from animals [19].

Solutions and Suspensions: Stability Challenges

Liquid formulations, particularly those prepared extemporaneously, encounter difficulties concerning stability and shelf-life due to interactions between the active pharmaceutical ingredient (API) and excipients, rather than conventional degradation mechanisms such as hydrolysis or photolysis. Several primary challenges and corresponding strategies to address them exist [20]:

1. *Interactions with Excipients:* Some medications such as hydralazine hydrochloride, isoniazid, and phenoxybenzamine hydrochloride experience diminished stability due to adverse interactions with excipients present in the formulation [21].
2. *Preservative Effects:* The inclusion of preservatives has the potential to influence stability. For instance, the impact of a preservative on reducing the pH of a levothyroxine sodium mixture led to a decline in stability [22].
3. *Packaging Material Influence:* The selection of packaging material can exert an influence on the stability of the formulation. It is imperative to verify that the container does not compromise the stability of the liquid dosage form or leach potentially harmful substances [23].
4. *Stability Testing:* Thorough stability assessments are imperative for every formulation to guarantee both its quality and safety. Stability evaluation should be conducted employing robust methods, such as forced degradation studies and method validation, to establish stability-indicating properties [24].
5. *Compatibility Testing:* Evaluating the compatibility of the container with the liquid formulation during stability testing under typical conditions of usage is crucial to mitigate any potential negative impacts on stability [25].
6. *Uniformity Testing:* Although not obligatory in stability investigations, performing assessments for the uniformity of dosage units is essential to guarantee consistent accuracy in dosing and maintain product quality [26].
7. *pH Monitoring:* It is imperative to monitor pH levels in liquid dosage forms as alterations in acidity can profoundly impact solubility and trigger degradation mechanisms. This underscores the criticality of vigilantly observing pH levels to uphold the integrity of pharmaceutical products [27.

Topical Formulations: Creams, Ointments, Patches

Applications and Recent Advancements

Topical preparations serve as targeted remedies for a range of ailments such as pain management, inflammation, and infections, with direct application onto the skin or mucosal surfaces. This

administration route circumvents initial liver metabolism, potentially boosting drug effectiveness by increasing bioavailability. Innovations in transdermal delivery mechanisms have emerged to optimize drug absorption and retention, thereby enhancing therapeutic outcomes, and fostering patient adherence [28].

- *Creams and Ointments:* Semisolid preparations like creams and ointments represent formulations well-suited for straightforward application onto the skin. These are commonly employed for targeted treatment of localized ailments such as dermatitis, psoriasis, and eczema. Creams typically exhibit a greater water content and are prone to easier removal upon washing, whereas ointments contain higher levels of oils, providing a more occlusive barrier that aids in moisture retention and facilitates enhanced drug permeation [29].
- *Patches:* Transdermal patches constitute a category of topical formulations engineered to administer drugs via the skin. Engineered for controlled drug release over prolonged durations, they offer advantages for conditions necessitating sustained therapy. Advancements in patch technology, notably the integration of microemulsions, have demonstrated potential in enhancing drug permeation and bioavailability [30].
- *Penetration Enhancers:* The efficacy of topical formulations can be hindered by the skin's inherent barrier properties. Chemical penetration enhancers (CPEs) are frequently employed to surmount this obstacle. These agents have the capacity to augment drug penetration either through structural modifications to the skin or by interacting with the drug molecules, thus amplifying their permeability [31].

Recent Patents and Innovations

Recent patent filings and scholarly investigations have prioritized the development of novel drug delivery methodologies tailored for local anesthetics. Such innovations aim to diminish the requisite drug concentration, enhance its permeability and absorption rates, and extend the duration of anesthetic or analgesic efficacy. These systems encompass a variety of approaches, including encapsulation within liposomes, complexation utilizing cyclodextrins, incorporation into biopolymers, and other carrier modalities [32].

Advanced Drug Delivery Systems

Nanotechnology-Based Delivery

Drug delivery systems based on nanotechnology leverage nanomaterials to achieve precise drug targeting and employ sophisticated mechanisms. Recent advancements in this domain have underscored the potential for enhancing drug effectiveness, mitigating adverse effects, and ultimately optimizing patient outcomes. Contemporary research sheds light on diverse facets of nanotechnology-based drug delivery.

- *Principles:* Nanotechnology facilitates the targeted delivery of medications to specific cellular destinations, such as cancer cells, while mitigating effects on healthy cells. Nanocarriers are engineered to envelop drugs and discharge them at designated locales, thereby augmenting drug effectiveness and diminishing toxicity levels [33].
- *Nanoparticle Synthesis:* Nanoparticles can be produced through the utilization of diverse materials including nanometal particles, polymers, and biological substances. There is a growing trend towards the integration of green chemistry principles in the development of nanodrug delivery systems, aiming to ensure environmentally sustainable practices [34].
- *Targeting Mechanisms:* Nanotechnology facilitates precise drug delivery to solid tumors via nano-targeted drug-delivery systems, enabling regulated drug release and augmenting the anticancer efficacy of traditional Chinese medicine (TCM) compounds [35].
- *Recent Breakthroughs:* The utilization of Quality-by-Design principles is being adopted to enhance the advancement of pharmaceuticals based on nanotechnology, with the aim of guaranteeing their quality and effectiveness [36]. Moreover, the progress in the development of RNA vaccines based on nanotechnology has demonstrated potential in addressing illnesses such as COVID-19, underscoring the efficacy of this methodology in vaccine creation [37].

Biodegradable and Implantable Systems

Biodegradable drug delivery systems have garnered considerable interest due to their capacity to facilitate controlled drug release while mitigating adverse effects. Below is a synthesis of the progress and utilization of biodegradable drug delivery systems derived from the provided search findings.

Biodegradable Polyesters for Implantable Controlled-Release Devices:

- *Development:* Synthetic biodegradable polyesters are employed in implantable devices to achieve sustained drug release. These polymers possess favorable characteristics suitable for diverse applications, including pain management, cancer therapy, contraception, and antiviral therapy.
- *Applications:* Biodegradable polyester-based implants ensure secure and consistent drug delivery, exhibiting elevated bioavailability and minimal toxicity. Depending on the design and deployment location, they can provide either localized or systemic drug release [38, 39].

Microemulsion-Based Polymer Matrix Transdermal Patch

- *Development:* Microemulsion patches represent an innovative drug delivery system wherein drugs in micron dimensions penetrate the skin more efficiently compared to conventional patches. These patches employ a transparent solution where the drug is encapsulated within a dispersed phase within a continuous phase, serving as the medium for drug administration.
- *Applications:* Microemulsion patches have demonstrated improved bioavailability and prolonged duration of efficacy in contrast to conventional patches, rendering them a promising option for the treatment of inflammation [40, 41].

Wireless Biodegradable Implantable Sensors:

- *Development:* There is growing interest in wireless biodegradable implantable sensors for postoperative monitoring, especially for short-term monitoring without requiring additional surgery for device removal. These sensors employ wireless communication to mitigate inflammation and infections commonly associated with long-term implants.
- *Applications:* Microfabricated biodegradable sensors hold promise for acute biomedical applications, yet their intricate design complexity at small scales necessitates further exploration before clinical integration [42,43].

Targeted Delivery Systems

Targeted drug delivery strategies are pivotal for enhancing the effectiveness and precision of pharmacological interventions. Essential methodologies encompass ligand-mediated targeting, antibody-drug conjugates (ADCs), and stimuli-responsive delivery systems [44].

Ligand-Mediated Targeting

Ligand-mediated targeting entails the conjugation of specific ligands to therapeutic agents or nanocarriers, facilitating the selective targeting of particular cells or tissues. For instance, in the realm of hepatocellular carcinoma (HCC), ligands such as asialoglycoprotein, galactoside, and antibodies have been employed to augment drug delivery to hepatocytes, thereby enhancing treatment efficacy [45].

Antibody-Drug Conjugates (ADCs)

Antibody-drug conjugates (ADCs) represent a class of targeted therapeutic interventions merging the targeted specificity inherent in monoclonal antibodies with the cytotoxic properties of chemotherapy agents. This strategy enables the precise administration of potent pharmaceuticals to cancerous cells, thereby mitigating adverse effects on non-cancerous tissues [46].

Stimuli-Responsive Delivery Systems

Stimuli-responsive drug delivery platforms are engineered to discharge medications upon encountering stimuli, such as variations in pH, temperature, or enzyme concentrations within the

physiological milieu. Such systems provide regulated drug release precisely at the intended site, thereby amplifying therapeutic efficacy [47].

Studies have demonstrated the potential of targeted drug delivery systems across diverse domains such as cancer therapy, disorders associated with mitochondrial dysfunction, and tumors of the central nervous system. Although substantial advancements have been achieved in preclinical investigations, the translation of these methodologies into clinically sanctioned treatments faces hurdles. Ongoing endeavors focus on devising innovative approaches to surmount biological obstacles and refine the accuracy and efficacy of targeted drug delivery systems [48].

Personalized Drug Delivery Systems

Novel advancements within personalized medicine, including the utilization of 3D printing for dosage form fabrication, pharmacogenomics-informed therapeutic strategies, and digital health innovations, are fundamentally transforming drug delivery systems to accommodate the unique requirements of individual patients [49].

- *3D Printing of Dosage Forms:* The utilization of 3D printing facilitates the creation of customized or distinctive dosage formats featuring intricate drug-release characteristics. This technological innovation enables the development of controlled drug delivery platforms specifically customized for individual patients [50]**.**
- *Pharmacogenomics-Guided Therapy:* Pharmacogenomics entails leveraging genetic data to inform decisions regarding drug therapy. Through comprehending the impact of an individual's genetic composition on their reaction to medications, healthcare professionals can tailor treatment regimens to enhance effectiveness and minimize adverse reactions [51].
- *Digital Health Solutions:* Incorporating personalized drug delivery systems into digital health platforms enhances patient care by facilitating remote monitoring, data aggregation, and the implementation of personalized treatment approaches. These integrated solutions enhance medication adherence and contribute to improved overall health outcomes [52].

The progression of personalized medicine is revolutionizing drug delivery by offering customized treatments that account for individual diversities in genetics, physiology, and lifestyle elements. These pioneering methods show significant potential in enhancing patient outcomes and optimizing therapeutic strategies across a spectrum of medical conditions [53].

Challenges and Opportunities

Regulatory Considerations

The progression and market introduction of innovative drug delivery platforms encounter numerous regulatory challenges and factors to be considered. These encompass:

1. *Characterization of Physicochemical Properties:* Ensuring that the drug delivery system aligns with the requisite physicochemical characteristics is paramount to ensuring both safety and efficacy [54].
2. *Pharmacodynamics and Pharmacokinetics:* Comprehending the impact of the drug delivery system on the pharmacokinetic and pharmacodynamic properties of the drug is fundamental for assessing its safety and efficacy [55].
3. *Process Control:* Guaranteeing the uniformity of manufacturing procedures and implementing rigorous quality control measures is imperative to achieve consistent outcomes and ensure safety [56].
4. *Biocompatibility and Nanotoxicity:* Evaluating the biocompatibility of the drug delivery system and its potential adverse effects is pivotal for ensuring safety [57].
5. *Scale-up and Reproducibility:* Expanding the production process while upholding consistent quality and safety standards poses a noteworthy challenge.
6. *Regulatory Bodies:* Adherence to regulatory directives set forth by entities like the FDA and EMA is essential for the authorization and marketing approval of innovative drug delivery systems.

7. *Risk-Based Approach:* Utilizing a risk-based approach from the initial phases of research and development can contribute to ensuring both safety and efficacy in the development of innovative nano-based dosage forms.
8. *Product Quality Assessment:* The evaluation of the drug delivery system's quality, encompassing its physicochemical attributes and manufacturing procedures, is indispensable for ensuring both safety and efficacy [58].
9. *Product Safety Assessment:* Assessing pharmacokinetics, biodegradability, accumulation, and nanotoxicity is imperative to guarantee safety [54].
10. *Intellectual Property:* Patents serve as a means to safeguard inventive advancements in fiber-based drug delivery systems.
11. *Commercial Advancements:* Commercialized products that have effectively utilized innovative drug delivery systems can serve as exemplars for future development [59].
12. *Regulatory Perspective:* The assessments conducted by global regulatory agencies are essential to guaranteeing the safety and efficacy of novel drug delivery systems.

These considerations underscore the interdisciplinary aspect involved in the development and commercialization of novel drug delivery systems. This necessitates collaboration among researchers, industry professionals, and regulatory bodies to uphold the safety and efficacy of these pioneering therapies [60].

Safety and Toxicity Concerns in Advanced Drug Delivery Technologies

Advanced drug delivery technologies aspire to augment treatment effectiveness while mitigating adverse reactions. Biocompatibility and toxicity are pivotal factors to contemplate in the progression of these technologies.

- ***Chitosan-Based Nanoparticles:*** Chitosan-derived nanomaterials are attracting interest due to their biodegradability, biocompatibility, and lack of toxicity. They demonstrate potential in diverse biomedical uses, notably drug delivery. Issues regarding bactericidal characteristics, safety/toxicity, and environmental consequences are being investigated through tissue culture and animal model research [60, 61].
- ***Engineered IL-12 Delivery System:*** A pioneering strategy entails employing a tumor-targeted drug delivery system to augment the effectiveness of IL-12 immunotherapy while mitigating toxicity. Through the fusion of IL-12 with a collagen binding domain (CBD), targeted transportation to the tumor stroma is realized. This method demonstrated robust anti-tumor efficacy with negligible peripheral toxicity [62].
- ***Porous Silicon for Biomedical Applications:*** Porous silicon (PSi) exhibits distinctive properties that are beneficial for drug delivery systems. Nonetheless, comprehending its biocompatibility and potential implications for human health is imperative. Ongoing research endeavors involve evaluating the toxicity of PSi-based materials through in vitro and in vivo assays [63].
- *CEB-01 Drug Delivery Implant Matrix:* CEB-01, an innovative drug delivery implant matrix containing SN-38, demonstrates potential in effectively managing recurrent soft tissue sarcoma while minimizing systemic toxicity. Initial safety findings from a pioneering clinical trial suggest promising advantages in local disease control and patient survival for individuals with recurrent or locally advanced retroperitoneal soft tissue sarcoma [64].
- *Advanced Vesicular Systems for Antifungal Drug Delivery:* Cutting-edge vesicular carriers are under investigation for efficiently encapsulating antifungal medications while mitigating systemic adverse effects. These platforms present enhanced stability, solubility, bioavailability, safety, and efficacy in contrast to conventional delivery approaches [65].

Economic Implications and Market Adoption of Drug Delivery Innovations

The economic terrain surrounding innovations in drug delivery is intricate, involving factors such as cost-effectiveness, market reception, and reimbursement deliberations. Various significant insights gleaned from the search outcomes illuminate this subject.

1. *Liquid Filled Hard Shell Capsules:* Liquid-filled hard-shell capsules are under investigation as a promising avenue for drug delivery, attributed to their capacity to augment bioavailability and safeguard delicate drug compounds. These capsules present varied functionalities for both immediate and sustained drug release, thereby enhancing therapeutic efficacy and patient convenience [66, 67].
2. *Institute for Clinical and Economic Review (ICER):* ICER conducts assessments of the clinical and economic worth of healthcare interventions, encompassing prescription medications. Their analyses furnish a "value-based price benchmark" to steer drug pricing toward enhancing patient outcomes in the long run. Additionally, ICER evaluates the immediate budgetary implications of new drugs to apprise payers and policymakers about potential pressures on healthcare system budgets [68, 69].
3. *Malaria Control:* Advancements in service delivery, such as novel public sector distribution systems for vital medications, have proven effective in expanding access to efficacious malaria treatment. Assessments conducted in low-income nations underscore the significance of resolving obstacles within drug supply networks to enhance health outcomes and socio-economic conditions [70].
4. *Oral vs. Intravenous Formulations:* The emergence of novel oral formulations as substitutes for intravenous drugs can influence patients' quality of life, disease prognosis, and healthcare expenses. Economic assessments are pivotal in advising policymakers on medication coverage strategies and assisting patients in their decision-making processes [71].
5. *Pharmacist's Role in Drug Delivery Systems:* The progressing field of drug delivery systems, integrating advancements like nanotechnology, RNA therapeutics, implantable devices, 3D printing, and artificial intelligence, is positioned to transform precision medicine. These developments strive to improve the effectiveness of treatments, adherence among patients, and address healthcare inequalities worldwide by providing personalized therapeutic solutions [72, 73].

Future Directions and Potential Breakthroughs

Future trends and potential breakthroughs in pharmaceutical drug delivery encompass multiple domains, such as immune checkpoint therapy targeting solid tumors, lipid-based nano-drug delivery platforms for dermal and transdermal applications, hydrogels utilized as drug delivery systems, nanomaterials facilitating targeted drug delivery via the skin, and nanoparticle-based drug delivery systems incorporating natural polymers for inflammatory bowel disease treatment.

1. *Immune Checkpoint Therapy for Solid Tumors:* Although immune checkpoint therapy holds promise for solid tumor treatment, unresolved clinical complexities and challenges underscore the necessity for continued research and potential advancements in this domain [74].
2. *Lipid-Based Nano-Drug Delivery Platforms:* Lipid-based nano-drug delivery platforms are emerging as notable trends in dermal and transdermal drug delivery, offering potential enhancements in drug delivery efficiency and addressing obstacles like decreased water solubility and sustained release requirements [75, 76].
3. *Hydrogels in Drug Delivery:* Due to their biocompatibility, biodegradability, flexibility, and non-toxic nature, hydrogels are extensively employed in drug delivery applications. Ongoing research efforts aim to innovate and improve upon existing hydrogels, potentially leading to breakthroughs in their utilization as distinctive drug delivery carriers [77, 78].
4. *Nanomaterials for Targeted Drug Delivery through the Skin:* The utilization of nanomaterials for targeted drug delivery through the skin is gaining traction owing to its convenience and cost-effectiveness. This method facilitates controlled and sustained drug release at designated sites, thereby enhancing drug accessibility, prolonged release, and metabolic stability [79, 80].
5. *Natural Polymer-Loaded Nanoparticle-Based Drug Delivery Systems:* Research is ongoing to create drug delivery systems based on nanoparticles loaded with natural polymers, aiming to counter challenges such as early drug release and pH changes in the gastrointestinal tract. These systems offer the potential to enhance bioavailability and require lower dosages to achieve therapeutic efficacy [81, 82].

CONCLUSION

The field of pharmaceutical drug delivery systems continues to evolve, driven by the imperative to enhance therapeutic efficacy, minimize adverse effects, and improve patient outcomes. From traditional dosage forms to advanced nanotechnology-based systems, each innovation aims to overcome specific challenges and optimize drug delivery mechanisms. Personalized medicine, characterized by tailored treatments and digital health solutions, is revolutionizing patient care. However, regulatory considerations, safety concerns, and economic implications present significant hurdles. Looking ahead, future breakthroughs in immune checkpoint therapy, lipid-based nano-drug delivery, hydrogels, nanomaterials, and natural polymer-loaded nanoparticles hold promise for addressing unmet medical needs. Collaboration among researchers, industry professionals, and regulatory bodies is crucial to navigate these challenges and ensure the safe and effective translation of innovative drug delivery systems into clinical practice.

REFERENCE

1. Hauck, Margarethe, et al. "Localized drug delivery systems in high-grade glioma therapy—from construction to application." Advanced Therapeutics 5.8 (2022): 2200013.
2. Sapowadia, Avin, et al. "Biomaterial Drug Delivery Systems for Prominent Ocular Diseases." Pharmaceutics 15.7 (2023): 1959.
3. Goel, Vasudha, et al. "Adverse events and complications associated with intrathecal drug delivery systems: insights from the manufacturer and user facility device experience (MAUDE) database." Neuromodulation: Technology at the Neural Interface 24.7 (2021): 1181-1189.
4. Kubelt, Carolin, et al. "Establishment of a Rodent Glioblastoma Partial Resection Model for Chemotherapy by Local Drug Carriers—Sharing Experience." Biomedicines 11.6 (2023): 1518.
5. Burdina, Olga B., and Olga G. Olekhnovich. "DENOMINATION OF DOSAGE FORMS IN RUSSIA: DEVELOPMENT OF THE TERMS." Perm University Herald. Russian & Foreign Philology/Vestnik Permskogo Universiteta. Rossijskaa i Zarubeznaa Filolgia 13.1 (2021).
6. Janczura, Magdalena, Szymon Sip, and Judyta Cielecka-Piontek. "The development of innovative dosage forms of the fixed-dose combination of active pharmaceutical ingredients." Pharmaceutics 14.4 (2022): 834.
7. Kawish, Syed M., et al. "Additive Manufacturing and Printing Approaches for the Development of Pharmaceutical Dosage Forms with Improved Biopharmaceutical Attributes." Current Drug Metabolism 23.8 (2022): 616-629.
8. Ozalp, Yildiz, et al. "Design and Development of Oxyclozanide Chewable Tablet Formulation Employing Quality by Design Approach." Indian Journal of Pharmaceutical Education & Research 57 (2023).
9. Waman, Ravi, et al. "QbD Approach in Formulation Design and Evaluation of Metformin HCl Tablet."
10. Mehetre, Gautam D., Rameshwar S. Cheke, and Vinayak N. Shrikhande. "Formulation and in-vitro evaluation of enteric coated tablet incorporating rabeprazole." Journal of Drug Delivery and Therapeutics 10.2-s (2020): 50-57.
11. Demir, Ersin, and Hulya Silah. "Development of a new analytical method for determination of veterinary drug oxyclozanide by electrochemical sensor and its application to pharmaceutical formulation." Chemosensors 8.2 (2020): 25.
12. Shete, Nikhil Arun, et al. "Optimization of Process Parameters for Formulation of Fluvastatin Tablet by Using Dry Granulation Method." *Journal of Drug Delivery and Therapeutics* 10.5-s (2020): 97-107.
13. Kaur, Gurpreet, D. B. Sridhar, and Manoj Gera. "Optimization of Roll Compaction/Dry Granulation (Rcdg) Process for Poorly Flowable Antiviral Formulation." Am J Pharmtech Res 2 (2012): 2249-3387.
14. 14, Hwang, Richard, and Robert M. Noack. "Application of design of experiments to pharmaceutical formulation development." International Journal of Experimental Design and Process Optimisation 2.1 (2011): 58-65.

15. Kalmer, Ramin Ramezani, et al. "Industrial Manufacture of Enteric Hard Capsules Using Novel Formulations Based on Hypromellose Phthalate/Gelatin and Investigation of Pantoprazole Release." ACS omega 8.12 (2023): 11293-11303.
16. Reddy, M. Sunitha, and Anusha Kunduru. "FORMULATION AND IN-VITRO EVALUATION OF GLIBENCLAMIDE DRY EMULSION IN VEGETARIAN CAPSULES." INDO AMERICAN JOURNAL OF PHARMACEUTICAL SCIENCES 4.11 (2017): 3869-3873.
17. Nie, Lei, et al. "Optimization of a coupling process for insulin degludec according to a Quality by Design (QbD) paradigm." AAPS PharmSciTech 19 (2018): 2185-2194.
18. Reddy, M., and M. Banu. FORMULATION AND IN-VITRO EVALUATION OF FENOFIBRATE DRY EMULSION IN HARD VEGETARIAN CAPSULES. 2018, www.semanticscholar.org/paper/FORMULATION-AND-IN-VITRO-EVALUATION-OF-FENOFIBRATE-Reddy-Banu/a448d104f0117b81bc2e66fe9d71906f392505bd.
19. Reddy, Madadi Sunitha, and Sai Tanmayee. "FORMULATION AND IN-VITRO EVALUATION OF DRY EMULSION OF MEFENAMIC ACID IN HARD VEGETARIAN CAPSULES." INTERNATIONAL JOURNAL OF PHARMACEUTICAL SCIENCES AND RESEARCH 9.9 (2018): 3985-3992.
20. Glass, Beverley D., and Alison Haywood. "Stability considerations in liquid dosage forms extemporaneously prepared from commercially available products." J Pharm Pharm Sci 9.3 (2006): 398-426.
21. Haywood, Alison, and Beverley Dawn Glass. "Liquid dosage forms extemporaneously prepared from commercially available products–considering new evidence on stability." Journal of Pharmacy & Pharmaceutical Sciences 16.3 (2013): 441-455.
22. Lam, Masha SH. "Extemporaneous compounding of oral liquid dosage formulations and alternative drug delivery methods for anticancer drugs." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 31.2 (2011): 164-192.
23. Jîtcă, Carmen-Maria, et al. "Stability of Oral Liquid Dosage Forms in Pediatric Cardiology: A Prerequisite for Patient's Safety—A Narrative Review." Pharmaceutics 15.4 (2023): 1306.
24. Silva, Márcio Robert Mattos da, et al. "Preparation of extemporaneous oral liquid in the hospital pharmacy." Brazilian Journal of Pharmaceutical Sciences 56 (2020).
25. Gillium, Charlotte, et al. "Stability of Extemporaneously Prepared Acetazolamide Oral Suspensions at Two Temperatures." The Journal of Pediatric Pharmacology and Therapeutics 25.8 (2020): 723-729.
26. Friciu, Mihaela, et al. "Stability of diazoxide in extemporaneously compounded oral suspensions." PLoS One 11.10 (2016): e0164577.
27. Friciu, Mihaela, V. Gaëlle Roullin, and Grégoire Leclair. "Stability of gabapentin in extemporaneously compounded oral suspensions." PLoS One 12.4 (2017): e0175208.
28. Casneuf, J., et al. "Oral Thrush in Children Treated with Miconazole Gel Die Behandlung der oralen Candidose bei Kindern mit Miconazol-Gel." Mycoses 23.2 (1980): 75-78.
29. Li, Peng, et al. "Development of Bioadhesive Transdermal Patches of Bupivacaine for the Enhancement of Anaesthetic Effect: Study in Rat Model." Journal of Biomaterials and Tissue Engineering 12.11 (2022): 2201-2207.
30. MITTAL, R., and R. BEE. "A REVIEW: MICROEMULSION-BASED POLYMER MATRIX TRANSDERMAL PATCH FOR THE TREATMENT OF INFLAMMATION." Journal of Pharmaceutical Negative Results (2022): 580-591.
31. Parhi, Rabinarayan, et al. "Novel penetration enhancers for skin applications: a review." Current Drug Delivery 9.2 (2012): 219-230.
32. de Paula, Eneida, et al. "Drug delivery systems for local anesthetics." Recent patents on drug delivery & formulation 4.1 (2010): 23-34.
33. Xu, Yi. "Nanomaterials used in cancer treatment based on drug delivery system." Third International Conference on Biological Engineering and Medical Science (ICBioMed2023). Vol. 12924. SPIE, 2024.

34. Jahangirian, Hossein, et al. "A review of drug delivery systems based on nanotechnology and green chemistry: green nanomedicine." International journal of nanomedicine (2017): 2957-2978.
35. Ma, Zhe, et al. "Traditional Chinese medicine-combination therapies utilizing nanotechnology-based targeted delivery systems: a new strategy for antitumor treatment." International journal of nanomedicine (2019): 2029-2053.
36. Rawal, Meghana, Amit Singh, and Mansoor M. Amiji. "Quality-by-design concepts to improve nanotechnology-based drug development." Pharmaceutical research 36 (2019): 1-20.
37. Pozharov, Vitaly P., and Tamara Minko. "Nanotechnology-Based RNA Vaccines: Fundamentals, Advantages and Challenges." Pharmaceutics 15.1 (2023): 194.
38. Pothupitiya, Jinal U., Christy Zheng, and W. Mark Saltzman. "Synthetic biodegradable polyesters for implantable controlled-release devices." Expert Opinion on Drug Delivery 19.10 (2022): 1351-1364.
39. Żółtowska, K., et al. "Development of biodegradable polyesters with various microstructures for highly controlled release of epirubicin and cyclophosphamide." European Journal of Pharmaceutical Sciences 96 (2017): 440-448.
40. MITTAL, R., and R. BEE. "A REVIEW: MICROEMULSION-BASED POLYMER MATRIX TRANSDERMAL PATCH FOR THE TREATMENT OF INFLAMMATION." Journal of Pharmaceutical Negative Results (2022): 580-591.
41. Alexander, Amit, et al. "Approaches for breaking the barriers of drug permeation through transdermal drug delivery." Journal of Controlled Release 164.1 (2012): 26-40.
42. De Santis, Michele, and Ilaria Cacciotti. "Wireless implantable and biodegradable sensors for postsurgery monitoring: Current status and future perspectives." Nanotechnology 31.25 (2020): 252001.
43. Park, Jongsung, et al. "A wireless pressure sensor integrated with a biodegradable polymer stent for biomedical applications." Sensors 16.6 (2016): 809.
44. Misra, Shashi Kiran, and Kamla Pathak. "Targeted drug delivery approaches for the management of tumors." Tumor Discovery 2.3 (2023): 1356.
45. Singh, Amrita, et al. "Ligand-mediated Targeted Drug Delivery Approaches against Hepatocellular Carcinoma." Current Cancer Drug Targets 23.11 (2023): 879-888.
46. Meng, Jianing, Vivek Agrahari, and Ibrahima Youm. "Advances in targeted drug delivery approaches for the central nervous system tumors: the inspiration of nanobiotechnology." Journal of Neuroimmune Pharmacology 12 (2017): 84-98.
47. Khan, Tanzeel, et al. "Mitochondrial Dysfunction: Pathophysiology and Mitochondria-Targeted Drug Delivery Approaches." Pharmaceutics 14.12 (2022): 2657.
48. Shah, Viral, and Pratiksha Kochar. "Brain cancer: implication to disease, therapeutic strategies and tumor targeted drug delivery approaches." Recent patents on anti-cancer drug discovery 13.1 (2018): 70-85.
49. Willemen, Niels GA, et al. "From oral formulations to drug-eluting implants: Using 3D and 4D printing to develop drug delivery systems and personalized medicine." Bio-Design and Manufacturing (2022): 1-22.
50. Basa, Bálint, et al. "The Application of 3D Printing in the Formulation of Personalized Drug Delivery Systems." Acta Pharmaceutica Hungarica 91.3-4 (2021): 179-180.
51. Zhang, Jiaxiang, et al. "Pharmaceutical additive manufacturing: a novel tool for complex and personalized drug delivery systems." AAPS PharmSciTech 19 (2018): 3388-3402.
52. Raijada, Dhara, et al. "Integration of personalized drug delivery systems into digital health." Advanced drug delivery reviews 176 (2021): 113857.
53. Govender, Rydvikha, et al. "Therapy for the individual: Towards patient integration into the manufacturing and provision of pharmaceuticals." European Journal of Pharmaceutics and Biopharmaceutics 149 (2020): 58-76.
54. Csóka, Ildikó, et al. "Regulatory considerations, challenges and risk-based approach in nanomedicine development." Current Medicinal Chemistry 28.36 (2021): 7461-7476.

55. Mühlebach, Stefan. "Regulatory challenges of nanomedicines and their follow-on versions: a generic or similar approach?." Advanced drug delivery reviews 131 (2018): 122-131.
56. Taha, Maie S., et al. "Critical quality attributes in the development of therapeutic nanomedicines toward clinical translation." Drug Delivery and Translational Research 10 (2020): 766-790.
57. Mhetre, Rani M., et al. "Liposome: An advanced pharmaceutical carrier in novel drug delivery system." International Journal of Science and Research Archive 10.2 (2023): 874-894.
58. Chien, Yie W. "Novel drug delivery systems." Drugs and the pharmaceutical sciences 50 (1992).
59. Dhoundiyal, Shivang, Aditya Sharma, and Md Aftab Alam. "Fiber Technology in Drug Delivery and Pharmaceuticals." Current Drug Delivery (2024).
60. Mehta, Prina, et al. "Recent applications of electrical, centrifugal, and pressurised emerging technologies for fibrous structure engineering in drug delivery, regenerative medicine and theranostics." Advanced drug delivery reviews 175 (2021): 113823.
61. Rizeq, Balsam R., et al. "Synthesis, bioapplications, and toxicity evaluation of chitosan-based nanoparticles." International journal of molecular sciences 20.22 (2019): 5776.
62. Ishihara, Jun. "Abstract IA011: Engineered IL-12 delivery to the tumor matrix to achieve enhanced efficacy and safety in multiple advanced tumors." Molecular Cancer Therapeutics 22.12_Supplement (2023): IA011-IA011.
63. Liu, D., et al. "Biocompatibility of porous silicon for biomedical applications." Porous silicon for biomedical applications. Woodhead Publishing, 2014. 129-181.
64. Gonzalez, José Antonio, et al. "First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report." (2021): 11554-11554.
65. Mosallam, Shaimaa, Rofida Albash, and Manar Adel Abdelbari. "Advanced vesicular systems for antifungal drug delivery." AAPS PharmSciTech 23.6 (2022): 206.
66. Nirale, Prabhuti, et al. "Liquid Filled Hard Shell Capsules: Current Drug Delivery Influencing Pharmaceutical Technology." Current Drug Delivery 19.2 (2022): 238-249.
67. Ma, Jia-Hua, et al. "A review on liquid-filled hard gelatin capsules." Zhongguo Zhong yao za zhi= Zhongguo Zhongyao Zazhi= China Journal of Chinese Materia Medica 33.5 (2008): 602-605.
68. Pearson, Steven. "Early experience with health technology assessment of gene therapies in the United States: pricing and paying for cures." Seminar Briefing. No. 002112. Office of Health Economics, 2019.
69. Iskrov, Georgi, Georgi Vasilev, and Rumen Stefanov. "What could gene therapies learn from orphan drugs' post-regulatory approval access in the EU?." Expert Opinion on Orphan Drugs 7.9 (2019): 407-414.
70. Friedman, Jed. Evidence for combating malaria. No. 75728. The World Bank, 2010.
71. Ronquest, Naoko A., et al. "Quantifying the Value of Introducing an Oral Drug Delivery Option for Edaravone: A Review of Analyses Evaluating the Economic Impact of Oral versus Intravenous Formulations." ClinicoEconomics and Outcomes Research (2022): 499-511.
72. Balogun, Obe Destiny, et al. "Innovations in drug delivery systems: A review of the pharmacist's role in enhancing efficacy and patient compliance." (2023).
73. Wang, Zhenzhen, and Yan Yang. "Application of 3D printing in implantable medical devices." BioMed Research International 2021 (2021).
74. Sun, Qian, et al. "Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends." Signal Transduction and Targeted Therapy 8.1 (2023): 320.
75. Singh, Siddharth, and Rajendra Awasthi. "Breakthroughs and bottlenecks of psoriasis therapy: Emerging trends and advances in lipid based nano-drug delivery platforms for dermal and transdermal drug delivery." Journal of Drug Delivery Science and Technology (2023): 104548.
76. Patil, Tulshidas S., et al. "Recent Advancements in Topical Anti-Psoriatic Nanostructured Lipid Carrier-Based Drug Delivery." International Journal of Molecular Sciences 24.3 (2023): 2978.
77. Hamidi, Esma, et al. "An overview on current trends and future outlook of hydrogels in drug delivery." Sigma: Journal of Engineering & Natural Sciences/Mühendislik ve Fen Bilimleri Dergisi 41.5 (2023).

78. Vashist, Arti, et al. "Recent advances in hydrogel based drug delivery systems for the human body." Journal of Materials Chemistry B 2.2 (2014): 147-166.
79. Mumtaz, Nazish, et al. "Nanomaterials for Targeted Drug Delivery through Skin to Treat Various Diseases: Recent Trends and Future Perspective." Journal of Chemistry 2023 (2023).
80. Zeb, Alam, et al. "Potential of nanoparticulate carriers for improved drug delivery via skin." Journal of pharmaceutical investigation 49 (2019): 485-517.
81. Basak, Ankita, et al. "Current trends and future perspectives of natural polymer loaded nanoparticle based drug delivery system for the management of inflammatory bowel disease." Journal of Applied Pharmaceutical Research 11.4 (2023): 01-09.
82. Mertins, Omar, Patrick D. Mathews, and Angelina Angelova. "Advances in the design of ph-sensitive cubosome liquid crystalline nanocarriers for drug delivery applications." Nanomaterials 10.5 (2020): 963.

